AstraZeneca is fronting $425 million, with an additional $575 million on the line to acquire Belgium-based EsoBiotec and its cell therapy-focused pipeline and platform, according to a news release on Monday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,